Mexico: Applying the experimental use exception in patent infringements

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mexico: Applying the experimental use exception in patent infringements

Sponsored by

olivares-400px.jpg
greyson-joralemon-9ibqihqhuhc-unsplash.jpg

Armando Arenas of Olivares explores how Mexico has interpreted the experimental and academic use exception

For many years, the experimental and academic use exception was incorrectly applied in Mexico to declare third parties who imported raw materials while the patents that protected the correlative active principle were still in force, as infringers. This is because the companies alleged that, according to their import requests, these authorisations had been granted by the sanitary authorities for experimentation purposes without commercial aims.

Therefore, to avoid patent infringement, it was sufficient for the defendant to exhibit the import authorisation granted by the sanitary authority (Federal Commission for the Protection against Sanitary Risks COFEPRIS). The import authorisation also had to include a legend stating that the importation had been authorised for experimentation purposes.

Additionally, some infringing companies enforced the Roche-Bolar exception and the experimental use exception at the same time, generating confusion in the Mexican Institute of Industrial Property (IMPI). The institute chose to declare the raw material importing companies (trading companies) as infringers, considering that their activity was only for commercial purposes and denied the infringement if the defendants proved that they were pharmaceutical companies applying the benefit of the Roche-Bolar exception.

Recently, in cases handled by Olivares, two different circuit courts have clarified the correct interpretation of the experimental and academic use exception. The rulings  stated, in accordance with the most basic rules of the burden of proof, that it was not enough to exhibit an import permit that indicates that the destination of the raw material to consider that such exception is applicable. It stated that it was however necessary to demonstrate with another type of evidence, as they constitute their own facts and it was the defendants who asserted the said exception, which is the type of activity that was specifically carried out for purely experimental purposes. These new criteria have now caused the IMPI to correctly apply this exception for the benefit of the patent protection system and its holders.

 
Armando ArenasPartner, OlivaresE: armando.arenas@olivares.mx  

more from across site and SHARED ros bottom lb

More from across our site

Licensing chief Patrik Hammarén also reveals that the company will rename its IPR business to better reflect its role in defining standards
The acquisition of Pecher & Partners follows the firm’s earlier expansion into litigation to create a ‘one-stop shop’
News of Via Licensing Alliance launching its first semiconductor patent pool and INTA electing a new president were also among the top talking points
Submit your nominations to this year's WIBL Americas Awards by January 23
The 2026 Life Sciences EMEA Awards is now open for entries. We are looking forward to reviewing and celebrating the industry's most impressive achievements and landmarks from the past year.
The tie-up between Perkins Coie and Ashurst may generate some striking numbers, but independent IP firms need not worry yet, according to practitioners
Perkins Coie’s US patent prosecution strength could provide Ashurst with an opportunity to enter an untapped market in Australia, but it may not be easy
Mitesh Patel at Reed Smith outlines why the US Copyright Office and courts have so far dismissed AI authorship and how inventors can protect AI-generated works
Xia Zheng, founder of AFD China, discusses balancing legal work with BD, new approaches to complex challenges, and the dangers of ‘over-optimism’
A dispute involving semiconductor technology and a partner's move from Hoffman Eitle to Hoyng Rokh Monegier were also among the top talking points
Gift this article